ResMed (ASX:RMD) reported Thursday fiscal third-quarter earnings of $2.37 per diluted share on a non-GAAP basis, up from $2.13 per diluted share a year earlier.
On a GAAP basis, diluted earnings per share rose to $2.58 from $2.04 year on year, the filing said.
Analysts polled by Visible Alpha were expecting EPS of $2.22.
Revenue for the three months ended March 31 was $1.29 billion, up 8% from $1.19 billion in the same period last year. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly dividend of $0.053 per share, up from the $0.048 in the previous reported period, payable on June 12 to shareholders on record as of May 8.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。